This should come as no surprise given that chronic inflammation is linked to a long list of illnesses including diabetes, cancer, and heart disease. Those with these underlying conditions have had difficult fending off more severe cases of these recent viruses.
The seriousness of inflammation is also evident by how many major pharmaceutical and healthcare companies are committing to research and development. The biggest brands in the world including Pfizer (NYSE:PFE), AbbVie (NYSE:ABBV), AstraZeneca (NASDAQ:AZN), and Gilead Sciences (NASDAQ:GILD) are all involved in researching inflammation to some degree.
Ludwig Enterprises (OTC:LUDG) the company that just recently switched its focus back to healthcare technology, is making inflammation its primary field of research. The company is utilizing artificial intelligence and data analytics to provide insight into massive patient databases.
Why has Ludwig chosen inflammation as its priority? It has already been recognized that chronic inflammatory diseases can be attributed to 50% of global mortality making it the single largest cause in the world. With an incredibly experienced and knowledgeable staff that has been put together and a new leadership team that has a long history in the healthcare industry, Ludwig is ready to provide research and potential therapies in the near future.
Featured: $PFE $ABBV $AZN $GILD $LUDG